Skip to main content

3 Result(s)

within I-M Dahl Remove this filter

and

  1. No Access

    Article

    No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease

    In this prospective randomized multicenter trial 93 patients, median age 72 years, with RAEB-t (n=25) and myelodysplastic syndrome (MDS)-AML (n=68) were allocated to a standard induction chemotherapy regimen (TAD...

    R Hast, E Hellström-Lindberg, L Ohm, M Björkholm, F Celsing, I-M Dahl… in Leukemia (2003)

  2. No Access

    Article

    Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support

    In a population-based study, the Nordic Myeloma Study Group found a survival advantage for high-dose melphalan with autologous blood stem-cell support compared to conventional chemotherapy in myeloma patients ...

    N. Gulbrandsen, F. Wisløff, L. Brinch, K. Carlson, I. M. Dahl… in Medical Oncology (2001)

  3. No Access

    Chapter

    High Molecular Weight Polysaccharides in Familial Cardiac Amyloid of Danish Origin Related to Transthyretin Met 111

    We have previously demonstrated a strong in vivo association between TTR Met 111 cardiac amyloid fibrils and glycosaminoglycans (1). The present study was aimed at investigating in more detail the macromolecul...

    J. H. Magnus, T. Stenstad, S. O. Kolset, I. M. Dahl… in Amyloid and Amyloidosis 1990 (1991)